HCG Stock Attracts Investors as Cancer Care Demand Surges

Spread love

With Nippon India, Morgan Stanley, and Motilal Oswal backing block deals, HCG strengthens its oncology leadership—supported by rising cancer prevalence, expanding centers, and bullish technical and financial momentum.

By S JHA

MUMBAI, September 13, 2025 — Healthcare Global Enterprises (HCG), India’s leading oncology care network, attracted strong institutional interest this week, with major block deals suggesting renewed investor confidence. Shares of Healthcare Global Enterprises closed at ₹678, with minor cuts on Friday.

“Nippon India Mutual Fund led the buying spree, acquiring 44 lakh shares at ₹695 apiece, joined by Morgan Stanley Asia Singapore (8.8 lakh shares), Plutus Wealth (7.2 lakh shares), and Motilal Oswal MF (3 lakh shares),” said StockEdge in a note shared on its Telegram channel.

The surge in institutional demand comes at a critical moment. India faces a mounting cancer challenge: 1 in 9 Indians may develop cancer by 2025, with early detection still abysmally low in breast, head-and-neck, and lung cancers. Against this backdrop, HCG has expanded to 25 centers across 19 cities, with 400+ oncologists, advanced LINAC radiotherapy platforms, robotic surgical systems, and genomics-driven diagnostics.

Financial Performance Snapshot (FY25):

Revenue: ₹2,223 crore
EBITDA Margin: 17.4%
PAT Margin: 2.0%
OPD footfall: 4.35 lakh
Robotic surgeries: 1,077
CAPEX: ₹206 crore

While profitability remains thin, HCG’s asset-light model (leasing, pay-per-use, hub-and-spoke) has enabled rapid scaling with lower capital intensity. Its revenue mix of 52% metros and 48% non-metros positions it well for India’s rising Tier-2/Tier-3 healthcare demand.

Technical Analysis: HCG stock has broken out from a consolidation zone on the daily charts, forming a bullish flag pattern—typically a continuation signal. The strong delivery volumes accompanying the breakout validate institutional accumulation.

Key support: ₹660–670 (recent breakout zone)
Immediate resistance: ₹730–740
Momentum indicators (RSI, MACD): bullish crossover, suggesting upside momentum.
Medium-term trend: Strong, with potential to retest ₹800+ if broader market sentiment holds.

Outlook: HCG’s dual strategy—expanding cancer care access beyond metros while integrating advanced diagnostics and robotics—aligns with India’s projected 13–14% oncology market CAGR. Backed by institutional inflows and improving operating efficiency, the stock is well-positioned for re-rating, though thin net margins remain a risk.

Shares of Healthcare Global Enterprises have risen by 36% in the last six months. The stock is in a consolidation phase for over a month now.

(Disclaimer: This article makes no recommendation for buy or sell of shares of any company)